Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France. // Respiratory Medicine and Research. – URL: https://www.sciencedirect.com/science/article/pii/S2590041225000856?dgcid=rss_sd_all
Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France. Respiratory Medicine and Research. https://www.sciencedirect.com/science/article/pii/S2590041225000856?dgcid=rss_sd_all
“Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France.” Respiratory Medicine and Research.
@article{article117664,
title = {Real-world outcomes of patients treated with ≥17 cycles of pembrolizumab monotherapy as first-line therapy and for previously treated advanced NSCLC: multicenter observational study in France},
journal = {Respiratory Medicine and Research},
url = {https://www.sciencedirect.com/science/article/pii/S2590041225000856?dgcid=rss_sd_all}
}